N-Acetyl Cysteine, a Glutamate-Modulating Agent, in the Treatment of Pathological Gambling: A Pilot Study

Biological Psychiatry

Volumn 62, Issue 6, 2007, Pages 652-657

  Grant, Jon E ^a   Kim, Suck Won ^a   Odlaug, Brian L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Addiction; amino acid; gambling; glutamate; pharmacology; treatment

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NUCLEUS ACCUMBENS; OPEN STUDY; PATHOLOGICAL GAMBLING; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACETYLCYSTEINE; ADULT; AGED; BEHAVIOR, ADDICTIVE; DOPAMINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMBLING; GLUTAMATES; HUMANS; MALE; MIDDLE AGED; NUCLEUS ACCUMBENS; PERSONALITY INVENTORY; PILOT PROJECTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 34548150512     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.11.021     Document Type: Article

References (37)

1. Argo T.A., and Black D.W. Clinical characteristics. In: Grant J.E., and Potenza M.N. (Eds). Pathological Gambling: A Clinical Guide to Treatment (2004), American Psychiatric Publishing, Washington DC 39-53
2. Baker D.A., McFarland K., Lake R.W., Shen H., Toda S., and Kalivas P.W. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci 1003 (2003) 349-351
3. Carlsson M.L. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 25 (2001) 5-26
4. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry 58 (2005) 424-428
5. Cunningham-Williams R.M., Cottler L.B., Compton III W.M., and Spitznagel E.L. Taking chances: Problem gamblers and mental health disorders-results from the St. Louis Epidemiologic Catchment Area study. Am J Public Health 88 (1998) 1093-1096
6. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0) (1995), Biometrics Research Department, New York State Psychiatric Institute, New York
7. Frisch M.B., Cornell J., and Villaneuva M. Clinical validation of the Quality of Life Inventory: A measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess 4 (1993) 92-101
8. Goldstein R.A., and Volkow N.D. Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159 (2002) 1642-1652
9. Grant J.E., and Kim S.W. Quality of life in kleptomania and pathological gambling. Compr Psychiatry 46 (2005) 34-37
10. Grant J.E., Levine L., Kim D., and Potenza M.N. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 162 (2005) 2184-2188
11. Grant J.E., and Potenza M.N. Compulsive aspects of impulse control disorders. Psychiatr Clin North Am 29 (2006) 539-551
12. rd ed. New York: Oxford University Press.
13. Grant J.E., Potenza M.N., Hollander E., Cunningham-Williams R., Nurminen T., Smits G., and Kallio A. A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163 (2006) 303-312
14. Grant J.E., Steinberg M.A., Kim S.W., Rounsaville B.J., and Potenza M.N. Preliminary validity and reliability testing of a structured clinical interview for pathological gambling (SCI-PG). Psychiatry Res 128 (2004) 79-88
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76-338 (1976), National Institute of Mental Health, Rockville, Maryland 218-222
16. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychiatry 32 (1959) 50-55
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
18. Hemby S.E., Tang W., Muly E.C., Kuhar M.J., Howell L., and Mash D.C. Cocaine-induced alterations in nucleus accumbens ionotropic glutamate receptor subunits in human and non-human primates. J Neurochem 95 (2005) 1785-1793
19. Hodgins D.C., and Petry N.M. Cognitive and behavioral treatments. In: Grant J.E., and Potenza M.N. (Eds). Pathological Gambling: A Clinical Guide to Treatment (2004), American Psychiatric Publishing, Washington DC 169-187
20. Hollander E., DeCaria C.M., Finkell J.N., Begaz T., Wong C.M., and Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry 47 (2000) 813-817
21. Hollander E., Pallanti S., Allen A., Sood E., and Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?. Am J Psychiatry 162 (2005) 137-145
22. Hollander E., Pallanti S., Baldini Rossi N., Sood E., Baker B.R., and Buchsbaum M.S. Imaging monetary reward in pathological gamblers. World J Biol Psychiatry 6 (2005) 113-120
23. Kalivas P.W., and Volkow N.D. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 162 (2005) 1403-1413
24. Kalivas P.W., Volkow N., and Seamans J. Unmanageable motivation in addiction: A pathology in prefrontal-accumbens glutamate transmission. Neuron 45 (2005) 647-650
25. Kim S.W., Grant J.E., Adson D.E., and Shin Y.C. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49 (2001) 914-921
26. Lafleur D.L., Pittenger C., Kelmendi B., Gardner T., Wasylink S., Malison R.T., et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacol 184 (2006) 254-256
27. LaRowe S.D., Mardikian P., Malcolm R., Myrick H., Kalivas P., McFarland K., et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 15 (2006) 105-110
28. Lochner C., Hemmings S.M.J., Kinnear C.J., Niehaus D.J.H., Nel D.G., Corfield V.A., et al. Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: Clinical and genetic correlates. Compr Psychiatry 46 (2005) 14-19
29. McFarland K., Lapish C.C., and Kalivas P.W. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 23 (2003) 3531-3537
30. Pallanti S., DeCaria C.M., Grant J.E., Urpe M., and Hollander E. Reliability and validity of the Pathological Gambling Modification of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambling Stud 21 (2005) 431-443
31. Pasternak A.V., and Fleming M.F. Prevalence of gambling disorders in a primary care setting. Arch Fam Med 8 (1999) 515-520
32. Peters J., and Kalivas P.W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl) 186 (2006) 143-149
33. Potenza M.N., Fiellin D.A., Heninger G.R., Rounsaville B.J., and Mazure C.M. Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med 17 (2002) 721-732
34. Rea L.M., and Parker R.A. Designing and Conducting Survey Research (1992), Jossey-Bass Publishers, San Francisco
35. Robinson T.E., and Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 17 (1997) 8491-8497
36. Shaffer H.J., Hall M.N., and Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: A research synthesis. Am J Pub Health 89 (1999) 1369-1376
37. Sheehan D.V. The Anxiety Disease (1983), Scribner's, New York